Immunotherapy plus chemo and avastin for resistant lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of immunotherapy (QL1706), chemotherapy, and bevacizumab (a drug that stops blood vessel growth) for people with a specific type of non-small cell lung cancer that has stopped responding to targeted therapy. It may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have non-small cell lung cancer (NSCLC) that is locally advanced or has spread (Stage IIIB-IVB)
- Your cancer has a specific mutation like EGFR, ALK, ROS1, RET, KRAS G12C, BRAF V600, or HER2 exon 20
- You have already tried at least one targeted therapy (like a TKI pill) and your cancer has grown despite it
- Your cancer has high PD-L1 (a protein that helps cancer hide from the immune system) — at least 50% of cells
- You have not had immunotherapy before
- You have no untreated or symptomatic brain metastases, and no active autoimmune disease or serious infections
- You are able to do light or full day activities (ECOG 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (QL1706) combined with bevacizumab, with or without chemotherapy, for people with advanced non-squamous non-small cell lung cancer that has grown after prior immunotherapy. It aims to see if this combination can help control the cancer.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.